CFIUS private equity considerations changed significantly with the Foreign Investment Risk Review Modernization Act (FIRRMA). The law broadened the Committee on Foreign Investment in the United States’ authority beyond transactions that transfer control of a U.S. business, bringing some non-controlling investments and real estate transactions within its potential reach. For private equity sponsors, that makes fund governance, limited partner rights, portfolio-company activities, and transaction planning important parts of investment review.
The details below reflect the framework and implementation developments described in 2018. CFIUS rules and filing requirements can change, so parties assessing a transaction should confirm the requirements applicable at the time of the deal with qualified counsel.
How FIRRMA broadened CFIUS review
CFIUS is an interagency committee authorized to assess national security implications of certain foreign investments in U.S. businesses. Depending on its review, the Committee may clear a transaction, determine it is outside its jurisdiction, require mitigation, suspend activity, or refer the matter to the President, who has authority to prohibit a pending transaction or order divestiture of a completed one.
Before FIRRMA, the Committee’s central focus was on transactions that could result in foreign control of a U.S. business. FIRRMA expanded the scope to include certain non-controlling investments in businesses connected to critical technology, critical infrastructure, or sensitive personal data. It also authorized review of some purchases, leases, and concessions involving U.S. real estate near sensitive government facilities or associated with air and maritime ports.
A minority investment may warrant particular scrutiny when it gives a foreign investor rights such as:
- Access to material non-public technical information held by the U.S. business.
- Board membership, observer rights, or the right to nominate a board representative.
- Participation, beyond voting shares, in substantive decisions about relevant technologies, infrastructure, or sensitive personal data.
The scope depends on the business’s activities and the investor’s rights—not simply the size of the equity stake. FIRRMA also addressed changes in an investor’s rights, meaning that amendments to an existing investment arrangement may require consideration as well.
CFIUS private equity fund carve-out: what to assess
FIRRMA created a potential carve-out for certain indirect investments made through investment funds. Under the framework described in the 2018 materials, the carve-out depended on conditions including exclusive management by a U.S. general partner, managing member, or equivalent; an advisory board that did not control investment decisions; and the foreign investor’s lack of control over the fund or access to material non-public technical information through advisory participation.
For sponsors, this is not a box-checking exercise. Fund documents and actual governance practices need to be considered together. Limited partner rights that create influence over fund decisions, access to sensitive information, or leverage over the manager may affect whether the conditions are met. A practical review can include questions such as:
- Who owns and manages the general partner and investment manager, and do non-U.S. persons hold roles within them?
- What rights do limited partners have, including approval, removal, information, or other affirmative and negative rights?
- Are any investors connected with foreign governments, and could those relationships affect the analysis?
- Could an investor’s other relationships with the sponsor provide influence beyond its formal fund rights?
- Do the fund’s investment focus and expected portfolio-company activities involve potentially covered sectors?
The same analysis can inform fundraising and co-investment planning. Investors, capital sources, syndication arrangements, and the allocation of governance rights may all matter when assessing the structure of an investment.
Critical technology, infrastructure, and personal data
FIRRMA identified three broad areas for expanded scrutiny: critical technology, critical infrastructure, and sensitive personal data. In 2018, an interim pilot program introduced mandatory declarations for certain transactions involving critical technologies used in or designed for specified industries. The program described in the source materials did not then implement the expanded non-controlling investment provisions for critical infrastructure or sensitive personal data.
Critical technology could include certain defense-related articles and services, controlled items, nuclear materials and equipment, select agents and toxins, and emerging or foundational technologies. The pilot program connected coverage to both the technology involved and the U.S. business’s activities in designated industries. Therefore, investors needed to look beyond a company’s headline product and examine what it produces, designs, tests, manufactures, or develops and how that work relates to relevant industries.
For critical infrastructure, the law focused on foreign investor access to technical information, governance rights, or involvement in substantive decisions concerning the management, operation, manufacture, or supply of covered infrastructure. For sensitive personal data, the relevant considerations included access and decision-making concerning the use, development, acquisition, safeguarding, or release of data that could be exploited in a way that threatens national security. The source materials noted that the term “sensitive personal data” was not defined there, leaving further detail to regulation.
Build CFIUS review into deal planning
FIRRMA extended the statutory initial review period from 30 to 45 days and authorized an additional 15-day extension to the investigation phase in extraordinary circumstances. The 2018 framework also introduced short declarations for certain transactions, with mandatory filing requirements in specified circumstances, including certain acquisitions by foreign-government-controlled entities. A declaration could lead to approval, a request for a full notice, or further review.
Statutory review periods do not capture all the time required to prepare and resolve a filing. Sponsors should account for pre-filing work, possible requests for additional information, and the risk that parties may need to withdraw and refile. Deal teams can also consider how CFIUS-related risks are handled in purchase agreements, including cooperation obligations, mitigation provisions, outside dates, syndication limits, and allocation of filing responsibilities.
Documentation is another practical safeguard. Fund agreements can address the conditions of the investment fund carve-out; transaction documents can reflect the parties’ intended rights and responsibilities; and portfolio-company governance and information-handling processes can help prevent rights or practices from creating unintended access or influence.
Practical implications for sponsors and operators
FIRRMA made national security review relevant to a wider range of investment structures, including some minority investments. Private equity teams should identify potentially sensitive business activities early, map foreign investors’ rights across the fund and portfolio company, and include review timing in transaction schedules. The central lesson is to evaluate not only who invests and how much, but also what the business does and what influence or access the investment provides. Early, coordinated diligence can help sponsors understand filing questions and address them in fund governance and deal documentation.